CO6541645A2 - Compuestos de indol y su uso farmaceutico - Google Patents

Compuestos de indol y su uso farmaceutico

Info

Publication number
CO6541645A2
CO6541645A2 CO12105036A CO12105036A CO6541645A2 CO 6541645 A2 CO6541645 A2 CO 6541645A2 CO 12105036 A CO12105036 A CO 12105036A CO 12105036 A CO12105036 A CO 12105036A CO 6541645 A2 CO6541645 A2 CO 6541645A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical use
indol compounds
diseases
indol
compounds
Prior art date
Application number
CO12105036A
Other languages
English (en)
Inventor
Teruhiko Inoue
Tetsudo Kaya
Koji Matsumura
Shinichi Kikuchi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CO6541645A2 publication Critical patent/CO6541645A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se provee un agente para el tratamiento o la prevención de enfermedades inflamatorias, enfermedades alérgicas, enfermedades autoinmunes, rechazo al trasplante o similares; un compuesto representado por la siguiente fórmula [I] o una de sus sales farmacéuticamente aceptables o uno de sus solvatos:en donde cada símbolo es tal como se describe en la memoria descriptiva.
CO12105036A 2009-11-25 2012-06-22 Compuestos de indol y su uso farmaceutico CO6541645A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25

Publications (1)

Publication Number Publication Date
CO6541645A2 true CO6541645A2 (es) 2012-10-16

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12105036A CO6541645A2 (es) 2009-11-25 2012-06-22 Compuestos de indol y su uso farmaceutico

Country Status (31)

Country Link
US (6) US8299070B2 (es)
EP (3) EP3059234A1 (es)
JP (6) JP5734628B2 (es)
KR (1) KR101766502B1 (es)
CN (1) CN102712624B (es)
AR (1) AR079164A1 (es)
AU (1) AU2010323579C1 (es)
BR (1) BR112012012529B1 (es)
CA (1) CA2781660C (es)
CL (1) CL2012001328A1 (es)
CO (1) CO6541645A2 (es)
CY (1) CY1117559T1 (es)
DK (1) DK2505586T3 (es)
ES (1) ES2572935T3 (es)
HK (1) HK1174025A1 (es)
HR (1) HRP20160579T1 (es)
HU (1) HUE028016T2 (es)
IL (1) IL220009A (es)
ME (1) ME02447B (es)
MX (1) MX2012006017A (es)
MY (1) MY161095A (es)
NZ (1) NZ600840A (es)
PE (1) PE20121358A1 (es)
PL (1) PL2505586T3 (es)
PT (1) PT2505586E (es)
RS (1) RS54910B1 (es)
RU (1) RU2556216C2 (es)
SI (1) SI2505586T1 (es)
SM (1) SMT201600258B (es)
TW (1) TWI491591B (es)
WO (1) WO2011065402A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
CN104994858A (zh) * 2012-11-02 2015-10-21 药品循环公司 Tec家族激酶抑制剂辅助疗法
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CN110845482B (zh) * 2014-07-04 2024-01-19 日本烟草产业株式会社 制备吲哚化合物的方法
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
US20210236503A1 (en) * 2018-05-25 2021-08-05 Japan Tobacco Inc. Therapeutic or preventing agent for multiple sclerosis including indole compound
US12011448B2 (en) 2018-05-25 2024-06-18 Japan Tobacco Inc. Therapeutic or preventing agent for nephrotic syndrome including indole compound
MX2020012644A (es) * 2018-05-25 2021-01-29 Japan Tobacco Inc Metodo para tratar dolor o cistitis intersticial utilizando compuesto de indol.
CN115087655A (zh) 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
US20240124439A1 (en) * 2020-12-15 2024-04-18 Pfizer Inc. Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
EP4263526A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease
CN117693502A (zh) * 2021-05-03 2024-03-12 纽力克斯治疗公司 用于抑制或降解itk的化合物、包含其的组合物、其制备方法及其使用方法
CA3217892A1 (en) * 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
AU2022370351A1 (en) * 2021-10-19 2024-05-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
DE60305446T4 (de) * 2002-01-07 2009-07-09 Eisai R&D Management Co., Ltd. Desazapurine und deren verwendung
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN100398545C (zh) * 2003-09-08 2008-07-02 安万特药物公司 噻吩并吡唑类化合物
KR20080011199A (ko) * 2005-04-19 2008-01-31 교와 핫꼬 고교 가부시끼가이샤 질소 함유 복소환 화합물
US20080293714A1 (en) * 2005-12-20 2008-11-27 Joerg Martin Bentzien Tec Kinase Inhibitors
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
CA2651732C (en) * 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
HUE028016T2 (en) 2016-11-28
SI2505586T1 (sl) 2016-08-31
DK2505586T3 (en) 2016-05-30
RU2012126129A (ru) 2013-12-27
BR112012012529A2 (pt) 2016-05-03
EP3766877A1 (en) 2021-01-20
JP2011132222A (ja) 2011-07-07
CL2012001328A1 (es) 2012-10-05
ES2572935T3 (es) 2016-06-03
US20180362506A1 (en) 2018-12-20
EP2505586A1 (en) 2012-10-03
SMT201600258B (it) 2016-08-31
JP2015172051A (ja) 2015-10-01
EP3059234A1 (en) 2016-08-24
KR101766502B1 (ko) 2017-08-08
BR112012012529B1 (pt) 2021-10-26
CN102712624A (zh) 2012-10-03
EP2505586A4 (en) 2013-05-15
NZ600840A (en) 2014-01-31
PL2505586T3 (pl) 2016-12-30
AU2010323579C1 (en) 2016-11-03
US20110306599A1 (en) 2011-12-15
CA2781660C (en) 2018-06-26
RU2556216C2 (ru) 2015-07-10
PE20121358A1 (es) 2012-10-23
JP2021091718A (ja) 2021-06-17
JP2017039761A (ja) 2017-02-23
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
US20200255408A1 (en) 2020-08-13
WO2011065402A1 (ja) 2011-06-03
US20130116240A1 (en) 2013-05-09
IL220009A (en) 2017-08-31
AU2010323579B2 (en) 2016-05-19
RS54910B1 (sr) 2016-10-31
EP2505586B1 (en) 2016-03-02
ME02447B (me) 2016-09-20
PT2505586E (pt) 2016-06-03
US20210284627A1 (en) 2021-09-16
JP5734628B2 (ja) 2015-06-17
AR079164A1 (es) 2011-12-28
MY161095A (en) 2017-04-14
CN102712624B (zh) 2014-06-04
JP2020079276A (ja) 2020-05-28
TW201124378A (en) 2011-07-16
US20170267662A1 (en) 2017-09-21
US8299070B2 (en) 2012-10-30
IL220009A0 (en) 2012-07-31
CY1117559T1 (el) 2017-04-26
AU2010323579A1 (en) 2012-07-19
HRP20160579T1 (hr) 2016-07-29
JP2018158935A (ja) 2018-10-11
CA2781660A1 (en) 2011-06-03
TWI491591B (zh) 2015-07-11
HK1174025A1 (zh) 2013-05-31

Similar Documents

Publication Publication Date Title
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
CL2013000351A1 (es) Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias.
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
CO6571861A2 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina y su uso como inhibidor de la integrasa del vih
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
DOP2011000260A (es) Pirimidinas fusionadas
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CL2011002180A1 (es) Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor.
DOP2014000152A (es) Inhibidores de bromodominios
AR077765A1 (es) Inhibidores de los virus flaviviridae
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
ECSP12012104A (es) Inhibidores de virus flaviviridae
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
EA201390885A1 (ru) Азаиндолы в качестве противовирусных агентов против респираторного синцитиального вируса
CL2013000378A1 (es) Combinacion farmaceutica que comprende un farmaco antipsicotico atipico, tal como risperidona y olanzapina, entre otros, y un compuesto derivado de piperazina-fenil-metanona, antagonista del receptor de glyt1; método de tratamiento; y su uso para el tratamiento de sintomas positivos y negativos de la esquizofrenia.
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos

Legal Events

Date Code Title Description
FG Application granted